hVIVO #HVO – Cathal Friel sells shares to satisfy institutional demand following capital markets event.  July 23, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has been notified that Cathal Friel, Chairman, sold 21,159,177 ordinary shares in the Company earlier today at 29p each to satisfy institutional demand post the Company’s recent capital markets event.  The shares sold were held through Raglan Road Capital Limited, a company owned and controlled by Cathal…